Table 1 Clinical features of twelve KRASG12C patient LUAD tumours, their derived xenografts and downstream organoids

From: Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms

Model (PHLC ID)

Stage

Sex

TP53 Mutation (PDX)

Gene Expression Subtype (PDX)

Long-Term Organoid From PDX

82

IB

F

M237I Q317*

TRU

Yes

151

IB

F

-

PP

Unsuccessful

191

IV

F

R181P

PP

Unsuccessful

194

IB

M

-

PI

Yes

207

IIA

F

R110L

TRU

Yes

237

IIB

F

-

PP

Unsuccessful

239

IA

M

-

PP

Yes

256

IB

M

Deep Del

PP

Unsuccessful

277

IIB

M

R337P

PP

Unsuccessful

334

IB

M

-

PP

Unsuccessful

344

IA

M

G199V

TRU

Yes

362

IIA

M

R158L

PI

Yes

  1. * Nonsense mutation.
  2. F female, M male, PP Proximal proliferative, PI Proximal inflammatory, TRU Terminal Respiratory Unit, PDX patient-derived xenograft.